As filed with the Securities and Exchange Commission on June 8, 2022 Registration No. 333-222713

_____________________

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________

POST-EFFECTIVE AMENDMENT NO. 1

TO

FORM F-6

REGISTRATION STATEMENT

under

THE SECURITIES ACT OF 1933

For American Depositary Shares

of

BIOFRONTERA AG

(Exact name of issuer of deposited securities as specified in its charter)

N/A

(Translation of issuer's name into English)

GERMANY

(Jurisdiction of incorporation or organization of issuer)

THE BANK OF NEW YORK MELLON

(Exact name of depositary as specified in its charter)

240 Greenwich Street, New York, New York 10286

(212) 495-1784

(Address, including zip code, and telephone number, including area code, of depositary's principal executive offices)

_______________________

The Bank of New York Mellon

Legal Department

240 Greenwich Street

New York, New York 10286

(212) 495-1784

(Address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Brian D. Obergfell, Esq.

Emmet, Marvin & Martin, LLP

120 Broadway

New York, New York 10271

(212) 238-3032

It is proposed that this filing become effective under Rule 466

[X] immediately upon filing

[ ] on (Date) at (Time).

If a separate registration statement has been filed to register the deposited shares, check the following box. [ ]

This Post-Effective Amendment is being filed solely to reflect that Biofrontera AG no longer files periodic reports with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended, but, instead, publishes information in English required to maintain the exemption from registration under Rule 12g3-2(b) under that Act.

The prospectus consists of the proposed Form of American Depositary Receipt included as Exhibit A to the Form of Deposit Agreement filed as Exhibit 1 to this Registration Statement which is incorporated herein by reference.

PART I

INFORMATION REQUIRED IN PROSPECTUS

Item -1. Description of Securities to be Registered

Cross Reference Sheet

Item Number and Caption			Location in Form of Receipt Filed Herewith as Prospectus
1.       Name and address of depositary			Introductory Article
2.       Title of American Depositary Receipts and identity of deposited securities			Face of Receipt, top center
Terms of Deposit:
(i)   The amount of deposited securities represented by one unit of American Depositary Receipts			Face of Receipt, upper right corner
(ii)   The procedure for voting, if any, the deposited securities			Articles number 15, 16 and 18
(iii)   The collection and distribution of dividends			Articles number 4, 12, 13, 15 and 18
(iv)  The transmission of notices, reports and proxy soliciting material			Articles number 11, 15, 16 and 18
(v)   The sale or exercise of rights			Articles number 13, 14, 15 and 18
(vi)  The deposit or sale of securities resulting from dividends, splits or plans of reorganization			Articles number 12, 13, 15, 17 and 18
(vii)  Amendment, extension or termination of the deposit agreement			Articles number 20 and 21
(viii)  Rights of holders of Receipts to inspect the transfer books of the depositary and the list of holders of Receipts			Article number 11
(ix)  Restrictions upon the right to deposit or withdraw the underlying securities			Articles number 2, 3, 4, 5, 6, 7, 8, 21 and 22
(x)   Limitation upon the liability of the depositary			Articles number 14, 18, 21 and 22
3.       Fees and Charges			Articles 7 and 8
	Item - 2.	Available Information
		Public reports furnished by issuer	Article number 11

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

Item - 3. Exhibits

a.	Form of Deposit Agreement dated as of February 13, 2018 among Biofrontera AG, The Bank of New York Mellon, as Depositary, and all Owners and Holders from time to time of American Depositary Shares issued thereunder. - Filed herewith as Exhibit 1.
b.	Any other agreement to which the Depositary is a party relating to the issuance of the Depositary Shares registered hereby or the custody of the deposited securities represented. - Not Applicable.
c.	Every material contract relating to the deposited securities between the Depositary and the issuer of the deposited securities in effect at any time within the last three years. – See (a) above.
d.	Opinion of Emmet, Marvin & Martin, LLP, counsel for the Depositary, as to legality of the securities to be registered. – Filed previously.
e.	Certification under Rule 466. – Filed herewith as Exhibit 5.

Item - 4.

Undertakings

(a) The Depositary hereby undertakes to make available at the principal office of the Depositary in the United States, for inspection by holders of the ADSs, any reports and communications received from the issuer of the deposited securities which are both (1) received by the Depositary as the holder of the deposited securities, and (2) made generally available to the holders of the underlying securities by the issuer.

(b) If the amounts of fees charged are not disclosed in the prospectus, the Depositary undertakes to prepare a separate document stating the amount of any fee charged and describing the service for which it is charged and to deliver promptly a copy of such fee schedule without charge to anyone upon request. The Depositary undertakes to notify each registered holder of an ADS thirty days before any change in the fee schedule.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that all the requirements for filing on Form F-6 are met and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on June 8, 2022.

Legal entity created by the agreement for the issuance of American Depositary Shares for ordinary shares of Biofrontera AG

By:	The Bank of New York Mellon
	As Depositary
	By:	/s/ Lance Miller
	Name:	Lance Miller
	Title:	Vice President

Pursuant to the requirements of the Securities Act of 1933, Biofrontera AG has caused this Registration Statement to be signed on its behalf by the undersigned thereunto duly authorized, in the City of Leverkusen, Germany on June 8, 2022.

BIOFRONTERA AG

By:	/s/ Ludwig Lutter
Name:	Ludwig Lutter
Title:	Chief Financial Officer

Each person whose signature appears below hereby constitutes and appoints Ludwig Lutter his or her true and lawful attorneys-in-fact with power of substitution and resubstitution to sign in his or her name, place and stead in any and all capacities the Registration Statement and any and all amendments thereto (including post-effective amendments) and any documents in connection therewith, and to file the same with the Securities and Exchange Commission, granting unto each of said attorneys full power to act with or without the other, and full power and authority to do and perform, in his or her name and on his behalf, every act whatsoever which such attorneys, or any one of them, may deem necessary or desirable to be done in connection therewith as fully and to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact, or any of them, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities indicated on June 8, 2022.

/s/ Ludwig Lutter		Chief Financial Officer and Chairman of
Ludwig Lutter		Management Board (principal executive,
		financial, and accounting officer)
/s/ William K. T. Zours		Chairman of Supervisory Board
William K. T. Zours
/s/ Dr. Jörgen Tielmann		Vice chairman of supervisory board
Dr. Jörgen Tielmann
/s/ Helge Lubenow		Member of supervisory board
Helge Lubenow
/s/ Heikki Lanckriet		Member of supervisory board
Heikki Lanckriet
/s/ Karlheimz Schmelig		Member of supervisory board
Karlheimz Schmelig
BIOFRONTERA INC.
Authorized Representative in the United States
By:	/s/ Daniel Hakansson
Name:	Daniel Hakansson
Title:	Corporate Counsel

INDEX TO EXHIBITS

Exhibit

Number Exhibit

1	Form of Deposit Agreement dated as of February 13, 2018, among Biofrontera AG, The Bank of New York Mellon, as Depositary, and all Owners and Holders from time to time of American Depositary Shares issued thereunder.
5	Certification Under Rule 466.